Neurofibrillary tangle

Last updated

Microscopy of a cell with neurofibrillary tangles (marked by arrows) Histopathology of neurofibrillary tangles in Alzheimer's disease - annotated.jpg
Microscopy of a cell with neurofibrillary tangles (marked by arrows)

Neurofibrillary tangles (NFTs) are intracellular aggregates of hyperphosphorylated tau protein that are most commonly known as a primary biomarker of Alzheimer's disease. [1] NFTs also are present in numerous other diseases known collectively as tauopathies. Little is known about their exact relationship to the different pathologies, but it is typically recognized that tauopathy is an important factor in the pathogenesis of several neurodegenerative diseases. [2] [3]

Contents

NFTs consist primarily of a misfolded, hyperphosphorylated microtubule-associated protein known as tau, which abnormally polymerizes into insoluble filaments within cells. [1] [4] Under the electron microscope, these polymers of tau are seen to take two basic forms: paired helical filaments (PHFs) and straight filaments. [4] [1] [5] These basic types of tau filaments can vary structurally, especially in different tauopathies. [1] The filaments bundle together to form the neurofibrillary tangles that are evident under the light microscope. Classical NFTs are located within the neuronal cell body, although it is now recognized that abnormal, filamentous tau occurs also in neuronal dendrites and axons (referred to as neuropil threads) and the dystrophic (abnormal) neurites that surround neuritic Abeta plaques. [5] [1] Mature NFTs in cell bodies can have a torch-like or globose appearance, [5] depending on the type of neuron involved. When tangle-containing neurons die, the tangles can remain in the neuropil as extracellular "ghost tangles". [6] [1]

Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neurites (arrowhead) in the brain of a patient who had died with Alzheimer's disease. Immunostaining using an antibody to tau; scale bar=25 microns (0.025 millimeters) Tauopathy in Alzheimer's disease.jpg
Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neurites (arrowhead) in the brain of a patient who had died with Alzheimer's disease. Immunostaining using an antibody to tau; scale bar=25 microns (0.025 millimeters)

Formation

The precise mechanism of tangle formation is not completely understood. Tau protein normally binds to microtubules in cells, where it contributes to the formation and stabilization of these important components of the cytoskeleton. [4] In the tauopathies, tau molecules are hyperphosphorylated and they fold into the wrong shape; in this deviant state they cause other tau molecules to misfold and stick to one another, eventually forming abnormal filaments. The misfolded tau molecules appear to act as seeds that transform other tau molecules to the abnormal state, thereby multiplying and spreading in the brain by a prion-like mechanism. [4] [7] The role of hyperphosphorylation in this process is uncertain. One possibility is that hyperphosphorylation reduces the normal binding of tau to microtubules, freeing the protein to self-assemble into polymers, [8] but as of 2024, Michel Goedert and colleagues stated that "It is unknown if phosphorylation is necessary and/or sufficient for the assembly of tau into filaments in the brain". [4] These authors also note that filamentous tau in NFTs is marked by other posttranslational modifications that could influence its properties in disease. In any case, hyperphosphorylation and misfolding of tau are well-established characteristics of NFTs that likely are important in the development of tauopathies. [1] [7]

Three different maturation states of NFTs have been defined using anti-tau and anti-ubiquitin immunostaining. [9] At stage 0 there are morphologically normal pyramidal cells showing diffuse or fine granular cytoplasmic staining with anti-tau antibodies (in other words, the cells appear to be healthy with minimal presence of aberrant tau); at stage 1 some delicate, elongated inclusions are stained by antibodies to tau (these are early tangles); stage 2 is represented by the classic appearance of NFTs as seen with anti-tau immunostaining; stage 3 is exemplified by ghost tangles (tangles outside of cells where the host neuron has died), which are characterized by a reduced immunostaining for tau but marked immunostaining for ubiquitin. [9] In this sequence of events, the abnormal phosphorylation of tau occurs before the appearance of ubiquitin immunoreactivity. [10] Once formed, NFTs appear to last for a long time in the brain, possibly remaining for many years after the death of the neurons in which they are formed. [5] [1] Ghost tangles can become immunoreactive with antibodies to other proteins in the extracellular environment, such as Abeta. [1] [11]

Causes

Hypothetical illustration of how microtubules disintegrate with Alzheimer's disease TANGLES HIGH.jpg
Hypothetical illustration of how microtubules disintegrate with Alzheimer's disease

Genetics

In adult humans there are 6 different types ("isoforms") of tau protein. [12] The different tau isoforms range from 352 to 441 amino acids in length, and they influence the type of neurofibrillary pathology that is present in different tauopathies. An important segment of tau that regulates its binding to microtubules and also its anomalous self-assembly into fibrils is the repeat domain that consists of stretches of recurring amino acids; the repeat domain in tau contains either 3 or 4 Repeats (forming what are called "3R tau" and "4R tau"). There are also two different inserts in the amino terminal part of tau, whose presence or absence - along with either 3 or 4 repeats - define the 6 tau isoforms. [12] In some tauopathies, including progressive supranuclear palsy, corticobasal degeneration, and argyrophilic grain disease, the intracellular inclusions consist of 4R tau; in Pick disease the inclusions consist of 3R tau, and in Alzheimer's disease both 3R tau and 4R tau are involved in the formation of neurofibrillary tangles. [6] A healthy ratio of 3R tau to 4R tau (which normally is approximately 1:1 in the adult human brain) appears to be important in preventing tauopathy. [4]

In addition to these variations in normally expressed tau isoforms, missense mutations and mutations that affect the splicing of the genetic message for tau are associated with various tauopathies. [6] In 1998, mutations in the MAPT gene were linked to a type of frontotemporal dementia with Parkinsonism; in the brains of affected patients, abnormal tau filaments were found in both neurons and glial cells. [12] As of 2023, 65 different mutations had been identified that are involved in neurodegenerative tauopathies. [4]

Traumatic brain injury

Traumatic brain injury can refer to acute injury that generally occurs once (such as in automobile accidents) or chronic repetitive brain injury as occurs in boxing and certain other sports in which concussions are common, such as American football. [13] In cases of severe, acute traumatic brain injury, the protein amyloid beta (Aβ) (which is associated with amyloid plaques) can accumulate in the brain, often in the absence of tauopathy; [13] in contrast, tauopathy with neurofibrillary tangles and neuropil threads is the main abnormality following repetitive mild brain injury (a disorder referred to as chronic traumatic encephalopathy (CTE)), (previously called dementia pugilistica). [13] [14]

The distribution of tau pathology in CTE differs from that in other neurodegenerative disorders such as Alzheimer's disease. [14] In CTE, the early appearance of hyperphosphorylated tau in neurons (and astrocytes) is most obvious around blood vessels and in the depths of the sulci, where the shear forces during head impact are most impactful. These forces are thought to cause elongated structures such as blood vessels and axons to stretch abnormally, stimulating the abnormal accumulation of tau within cells. As CTE advances, tauopathy appears in an increasing number of brain areas. [14]

Aluminium

The idea that there is a link between aluminium (aluminum) exposure and the formation of neurofibrillary tangles has floated around the scientific community for some time without having been definitively proven or disproven. Aluminium is a metal that has no known function in living systems, [15] and it is well known to be neurotoxic in high doses. [16] It is the most ubiquitous metal in the earth's crust, so it is rather hard to avoid; the most common sources of aluminium exposure in humans are food, drinking water, and inhalation (aluminium exposure via vaccines is negligible). [16] Large amounts of aluminium have long been known to be toxic; for instance, in the early days of treatment, people undergoing hemodialysis for kidney failure were exposed to high levels of aluminium as part of the treatment, sometimes causing a serious disorder known as dialysis encephalopathy in which seizures and cognitive dysfunction are present. [17] Aluminium has been largely eliminated from dialysis treatments, so that today the risk of encephalopathy has been greatly reduced. [16]

In 1965, researchers injected aluminium into the brains of rabbits and noted that neurons developed inclusions that superficially resembled the neurofibrillary tangles of Alzheimer's disease. Subsequent research, however, has shown that the cytopathology caused by aluminium are different from that in Alzheimer's disease. [18] [19] Studies have detected aluminium in tangle-bearing neurons from Alzheimer patients, [20] [21] but it is not certain if the aluminium caused the tangles or simply binds to them, and the idea that aluminium is a cause of Alzheimer's disease per se has failed to gain wide acceptance in the field. [19] In addition, many other metals have been suggested to be risk factors for Alzheimer's disease, including zinc, copper, mercury, manganese, cadmium, and magnesium. [22] Given the current state of knowledge, it is reasonable to conclude that excessive aluminium is toxic to the brain, that it can cause seizures and dementia, and that it can induce abnormalities in neurons, but it does not appear to engender the neurofibrillary tangles that characterize naturally occurring human neurodegenerative disorders such as Alzheimer's disease. [19]

Pathology

It has been shown that the degree of cognitive impairment in diseases such as AD is significantly correlated with the presence of neurofibrillary tangles. [23]

Neuron loss

Traditionally believed to play a major role in neuron loss, NFTs are an early event in pathologies such as Alzheimer's disease, and as more NFTs form, there is substantially more neuron loss. However, it has been shown that there is significant neuron loss before the formation of neurofibrillary tangles, and that NFTs account for only a small proportion (around 8.1%) of this neuron loss. [24] Coupled with the longevity of neurons containing NFTs, it is likely that some other factor is primarily responsible for the bulk of neuron loss in these diseases, not the formation of neurofibrillary tangles.

It is currently unclear as to whether or not primary age-related tauopathy (PART), a term in which includes some cases formerly referred to as neurofibrillary tangle-predominant dementia (NFTPD) or tangle-only dementia, is a variant of the traditional Alzheimer's disease, or a distinct entity. Characterized by later onset and milder cognitive impairment, the distribution of NFT pathology is more closely related to that found in centenarians showing no or limited cognitive impairment. NFTs are generally limited to allocortical/limbic regions of the brain with limited progression to the neocortex but a greater density in the allocortical/hippocampal region. Plaques are generally absent. [25] [26]

Alzheimer disease with concomitant dementia with Lewy bodies (AD+DLB)

The degree of NFT involvement in AD is defined by Braak staging. Braak stages I and II are used when NFT involvement is confined mainly to the transentorhinal region of the brain. Stages III and IV are indicated when there is involvement of limbic regions such as the hippocampus, and V and VI when there's extensive neocortical involvement. This should not be confused with the degree of senile plaque involvement, which progresses differently. [27]

Neurofibrillary tangle and modified Braak scores were lower in AD+DLB, however, neocortical NFT scores show markedly different patterns between AD+DLB and Classical Alzheimer's. In pure AD, NFT are predominantly found at a high frequency: In AD+DLB, the distribution of NFT frequency was found to be bimodal: NFTs were either frequent or few to absent. Additionally, neocortical NFT frequency in the AD+DLB group tended to parallel the severity of other types of tau cytopathology. [28]

A recent study looked for correlation between the quantitative aspects of Alzheimer's disease (neuron loss, neuritic plaque and neurofibrillary tangle load) and aggression frequently found in Alzheimer's patients. It was found that only an increase in neurofibrillary tangle load was associated with severity of aggression and chronic aggression in Alzheimer's patients. [29] While this study does indicate a correlation between NFT load and severity of aggression, it does not provide a causative argument.

Research has also indicated that patients with AD and comorbid depression show higher levels of neurofibrillary tangle formation than individuals with AD but no depression. [30] Comorbid depression increased the odds for advanced neuropathologic disease stage even when controlling for age, gender, education and cognitive function. [30]

Treatment

Overview of RNA interference RNAi-simplified.svg
Overview of RNA interference

Statins

Statins have been shown to reduce the neurofibrillary tangle burden in mouse models, likely due to their anti-inflammatory capacities. [31]

Cyclin-dependent kinase 5

Cyclin-dependent kinase 5 (CDK5) is a kinase that has been previously hypothesized to contribute to tau pathologies. RNA interference (RNAi) mediated silencing of the CDK5 gene has been proposed as a novel therapeutic strategy against tau pathology, such as neurofibrillary tangles. Knockdown of CDK5 has been shown to reduce the phosphorylation of tau in primary neuronal cultures and in mouse models. Furthermore, this silencing showed a dramatic reduction in the number of neurofibrillary tangles. However, in conditions such as Alzheimer's disease, only about 1% is hereditary, and therefore RNAi therapy may be inadequate for addressing the needs of the majority of those who have this disease. [32]

Lithium

Lithium has been shown to decrease the phosphorylation of tau. [33] Lithium treatment has been shown to reduce the density of neurofibrillary tangles in transgenic models in the hippocampus and spinal cord. Despite the decrease in density of NFTs, motor and memory deficits were not seen to improve following treatment. Additionally, no preventive effects have been seen in patients undergoing lithium treatment. [33]

Curcumin

Curcumin has been shown to reduce memory deficit and tau monomers in animal models, however no clinical trials have shown curcumin to remove tau from the brain. [34]

Other conditions

See also

References

  1. 1 2 3 4 5 6 7 8 9 DeTure MA, Dickson DW (2019). "The neuropathological diagnosis of Alzheimer's disease". Molecular Neurodegeneration. 14 (32) 32. doi: 10.1186/s13024-019-0333-5 . PMC   6679484 . PMID   31375134.
  2. ↑ Alonso Ad, Li B, Grundke-Iqbal I, Iqbal K (2008). "Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies" . Current Alzheimer Research. 5 (4): 375–384. doi:10.2174/156720508785132307. PMID   18690834.
  3. ↑ Beharry C, Cohen LS, Di J, Ibrahim K, Briffa-Mirabella S, Alonso Ad (2014-04-01). "Tau-induced neurodegeneration: mechanisms and targets". Neuroscience Bulletin. 30 (2): 346–358. doi:10.1007/s12264-013-1414-z. ISSN   1995-8218. PMC   5562659 . PMID   24733656.
  4. 1 2 3 4 5 6 7 Goedert M, Crowther RA, Scheres SH, Spillantini MG (2024). "Tau and neurodegeneration". Cytoskeleton (Hoboken). 81 (1): 95–102. doi:10.1002/cm.21812. PMC   7615684 . PMID   38073060.
  5. 1 2 3 4 Hauw JJ, Duyckaerts C (2001). "Alzheimer's disease". In Duckett S, DeLaTorre JC (eds.). Pathology of the Aging Human Nervous System. Oxford University Press. pp. 207–263. ISBN   0-19-513069-3.
  6. 1 2 3 Duyckaerts C, Lowe J, Frosch M (2014). "Pathology of degenerative diseases of the nervous system". In Gray F, Duyckaerts C, De Girolami U (eds.). Basic Neuropathology. Oxford University Press. pp. 173–204. ISBN   978-0-19-992905-4.
  7. 1 2 Granholm AC, Hamlett ED (2024). "The role of tau pathology in Alzheimer's disease and Down syndrome". Journal of Clinical Medicine. 13 (5): 1338. doi: 10.3390/jcm13051338 . PMC   10932364 . PMID   38592182.
  8. ↑ Lee VM, Goedert M, Trojanowski JQ (2001). "Neurodegenerative tauopathies". Annual Review of Neuroscience. 24: 1121–1159. doi:10.1146/annurev.neuro.24.1.1121. PMID   11520930.
  9. 1 2 Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, Seitelberger F, Grundke-Iqbal I, Wisniewski HM, et al. (1989). "Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease". Brain Res. 477 (1–2): 90–99. doi:10.1016/0006-8993(89)91396-6. PMID   2495152. S2CID   23857381.
  10. ↑ Bancher C, Grundke-Iqbal I, Iqbal K, Fried VA, Smith HT, Wisniewski HM (1991). "Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease". Brain Research. 539 (1): 11–18. doi:10.1016/0006-8993(91)90681-k. PMID   1849776.
  11. ↑ Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW (2000). "Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly". Acta Neuropathologica. 100 (1): 36–42. doi:10.1007/s004010051190. PMID   10912918.
  12. 1 2 3 Goedert M, Spillantini MG (2017). "Propagation of Tau aggregates". Molecular Brain. 10 (1) 18. doi: 10.1186/s13041-017-0298-7 . PMC   5450399 . PMID   28558799.
  13. 1 2 3 DeKosky S. T., Ikonomovic M. D., Gandy S. (2010). "Traumatic Brain Injury -- Football, Warfare, and Long-Term Effects". New England Journal of Medicine. 363 (14): 1293–1296. doi:10.1056/NEJMp1007051. PMID   20879875.
  14. 1 2 3 McKee A, Stein TD, Kiernan PT, Alvarez VE (2015). "The neuropathology of chronic traumatic encephalopathy". Brain Pathology. 25 (3): 350–364. doi:10.1111/bpa.12248. PMC   4526170 . PMID   25904048.
  15. ↑ Exley C, House ER (2011). "Aluminium in the human brain". Monatsheft Fuer Chemie. 142 (4): 357–363. doi:10.1007/s00706-010-0417-y.
  16. 1 2 3 Brylinski L, Kostelecka K, Wolinski F, Duda P, Gora J, Granat M, Flieger J, Teresinski G, Buszewicz G, Sitarz R, Baj J (2023). "Aluminium in the human brain: Routes of penetration, toxicity, and resulting complications". International Journal of Molecular Sciences. 24 (8): 7228. doi: 10.3390/ijms24087228 . PMC   10139039 . PMID   37108392.
  17. ↑ Alfrey AC, LeGendre GR, Kaehny WD (1976). "The dialysis encephalopathy syndrome. Possible aluminum intoxication". The New England Journal of Medicine. 294 (4): 1533–4406. doi:10.1056/NEJM197601222940402. PMID   1244532.
  18. ↑ Reusche E, Seydel U (1993). "Dialysis-associated encephalopathy: light and electron microscopic morphology and topography with evidence of aluminum by laser microprobe mass analysis". Acta Neuropathologica. 86 (3): 249–258. doi:10.1007/BF00304139. PMID   8213083.
  19. 1 2 3 Lidsky TI (2014). "Is the Aluminum Hypothesis dead?". Journal of Occupational and Environmental Medicine. 56 (5): S73-79. doi:10.1097/JOM.0000000000000063. PMC   4131942 . PMID   24806729.
  20. ↑ Perl DP, Brody AR (1980). "Alzheimer's Disease: X-Ray Spectrometric Evidence of Aluminum Accumulation in Neurofibrillary Tangle-Bearing Neurons". Science. 208 (4441): 297–299. Bibcode:1980Sci...208..297P. doi:10.1126/science.7367858. PMID   7367858.
  21. ↑ Good PF, Perl DP, Bierer LM, Schmeidler J (1992). "Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study". Annals of Neurology. 31 (3): 286–292. doi:10.1002/ana.410310310. PMID   1637136.
  22. ↑ Armstrong RA (2019). "Risk factors for Alzheimer's disease". Folia Neuropathologica. 57 (2): 87–105. doi:10.5114/fn.2019.85929. PMID   31556570.
  23. ↑ Braskie M. N., Klunder A. D., Hayashi K. M., Protas H., Kepe V., Miller K. J., et al. (2010). "Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. [Article]". Neurobiology of Aging. 31 (10): 1669–1678. doi:10.1016/j.neurobiolaging.2008.09.012. PMC   2891885 . PMID   19004525.
  24. ↑ Kril J. J., Patel S., Harding A. J., Halliday G. M. (2002). "Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. [Article]". Acta Neuropathologica. 103 (4): 370–376. doi:10.1007/s00401-001-0477-5. PMID   11904757. S2CID   12986021.
  25. ↑ Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF (Nov 2012). "The MAPT H1 haplotype is associated with tangle-predominant dementia". Acta Neuropathol. 124 (5): 693–704. doi:10.1007/s00401-012-1017-1. PMC   3608475 . PMID   22802095.
  26. ↑ Santa-Maria I, Haggiagi, Aya, Liu, Xinmin, Wasserscheid, Jessica, Nelson, Peter T., Dewar, Ken, Clark, Lorraine N., Crary, John F. (2012). "The MAPT H1 haplotype is associated with tangle-predominant dementia". Acta Neuropathologica. 124 (5): 693–704. doi:10.1007/s00401-012-1017-1. PMC   3608475 . PMID   22802095.
  27. ↑ Braak H, Braak E (1991). "Neuropathological stageing of Alzheimer-related changes". Acta Neuropathologica. 82 (4): 239–59. doi:10.1007/BF00308809. PMID   1759558. S2CID   668690.
  28. ↑ Gearing, M., Lynn, M., & Mirra, S. S. (Feb 1999). "Neurofibrillary pathology in Alzheimer disease with Lewy bodies - Two subgroups". Archives of Neurology. 56 (2): 203–208. doi: 10.1001/archneur.56.2.203 . PMID   10025425.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  29. ↑ Lai M. K. P., Chen C. P., Hope T., Esiri M. M. (2010). "Hippocampal neurofibrillary tangle changes and aggressive behaviour in dementia". NeuroReport. 21 (17): 1111–1115. doi:10.1097/WNR.0b013e3283407204. PMID   20890229. S2CID   14317916.
  30. 1 2 Rapp M. A., Schnaider-Beeri M., Purohit D. P., Perl D. P., Haroutunian V., Sano M. (2008). "Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression". American Journal of Geriatric Psychiatry. 16 (2): 168–174. doi:10.1097/JGP.0b013e31816029ec. PMID   18239198.
  31. ↑ Boimel M., Grigoriadis N., Lourbopoulos A., Touloumi O., Rosenmann D., Abramsky O., et al. (2009). "Statins Reduce the Neurofibrillary Tangle Burden in a Mouse Model of Tauopathy. [Article]". Journal of Neuropathology and Experimental Neurology. 68 (3): 314–325. doi: 10.1097/NEN.0b013e31819ac3cb . PMID   19225406.
  32. ↑ Piedrahita D., Hernandez I., Lopez-Tobon A., Fedorov D., Obara B., Manjunath B. S., et al. (2010). "Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's Mice". Journal of Neuroscience. 30 (42): 13966–13976. doi:10.1523/JNEUROSCI.3637-10.2010. PMC   3003593 . PMID   20962218.
  33. 1 2 Leroy K., Ando K., Heraud C., Yilmaz Z., Authelet M., Boeynaems J. M., et al. (2010). "Lithium Treatment Arrests the Development of Neurofibrillary Tangles in Mutant Tau Transgenic Mice with Advanced Neurofibrillary Pathology" (PDF). Journal of Alzheimer's Disease. 19 (2): 705–719. doi:10.3233/JAD-2010-1276. PMID   20110614.
  34. ↑ Ma QL, Zuo X, Yang F, Ubeda O, Gant D, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA (2012). "Curcumin suppresses soluble tau oligomers and corrects molecular chaperone, synaptic and behavioral deficits in aged human tau transgenic mice". Journal of Biological Chemistry. 288 (6): 4056–65. doi: 10.1074/jbc.M112.393751 . PMC   3567657 . PMID   23264626.
  35. ↑ Williams DR, Lees AJ (2009). "Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges". The Lancet Neurology. 8 (3): 270–9. doi:10.1016/S1474-4422(09)70042-0. PMID   19233037. S2CID   1417930.
  36. ↑ Roberts GW (1988). "Immunocytochemistry of neurofibrillary tangles in dementia pugilistica and Alzheimer's disease: evidence for common genesis". Lancet. 2 (8626–8627): 1456–8. doi:10.1016/S0140-6736(88)90934-8. PMID   2904573. S2CID   32662671.
  37. ↑ Selkoe DJ, Podlisny MB (2002). "Deciphering the genetic basis of Alzheimer's disease". Annual Review of Genomics and Human Genetics. 3 (1): 67–99. doi: 10.1146/annurev.genom.3.022502.103022 . PMID   12142353.
  38. ↑ Hof PR, Nimchinsky EA, Buée-Scherrer V, et al. (1994). "Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders". Acta Neuropathol. 88 (5): 397–404. doi:10.1007/BF00389490. PMID   7847067. S2CID   2821768.
  39. ↑ Brat DJ, Gearing M, Goldthwaite PT, Wainer BH, Burger PC (2001). "Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype". Neuropathology and Applied Neurobiology. 27 (3): 197–205. doi:10.1046/j.1365-2990.2001.00311.x. PMID   11489139. S2CID   36482221.
  40. ↑ Halper J, Scheithauer BW, Okazaki H, Laws Jr ER (1986). "Meningio-angiomatosis: a report of six cases with special reference to the occurrence of neurofibrillary tangles". Journal of Neuropathology and Experimental Neurology. 45 (4): 426–46. doi:10.1097/00005072-198607000-00005. PMID   3088216. S2CID   663552.
  41. ↑ Paula-Barbosa MM, Brito R, Silva CA, Faria R, Cruz C (1979). "Neurofibrillary changes in the cerebral cortex of a patient with subacute sclerosing panencephalitis (SSPE)". Acta Neuropathologica. 48 (2): 157–60. doi:10.1007/BF00691159. PMID   506699. S2CID   36105401.
  42. ↑ Wisniewski K, Jervis GA, Moretz RC, Wisniewski HM (1979). "Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia". Annals of Neurology. 5 (3): 288–94. doi:10.1002/ana.410050311. PMID   156000. S2CID   25649751.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.